Solesence, INC. (SLSN) — SEC Filings

Overview

Solesence, INC. (SLSN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K/A filed on Apr 23, 2026: Solesence, Inc. filed an amendment to its annual report on Form 10-K/A on April 23, 2026, for the period ending December 31, 2025. The filing includes certifications from its CEO and CFO, as well as a clawback policy. The company is in the perfumes, cosmetics, and other toilet preparations industry.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 36 neutral. The dominant filing sentiment for Solesence, INC. is neutral.

Filing Type Overview

Solesence, INC. (SLSN) has filed 1 10-K/A, 22 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 4 SC 13D/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Solesence, Inc. Files 10-K/A Amendment — 10-K/A · Apr 23, 2026 Risk: low
  Solesence, Inc. filed an amendment to its annual report on Form 10-K/A on April 23, 2026, for the period ending December 31, 2025. The filing includes certifica
• Solesence, Inc. Files 8-K for Q1 2026 Financials — 8-K · Mar 31, 2026 Risk: low
  Solesence, Inc. filed an 8-K on March 31, 2026, reporting its results of operations and financial condition for the period ending March 31, 2026. The filing inc
• 8-K Filing — 8-K · Dec 3, 2025
• Solesence, Inc. Files 8-K: Agreements, Officer Changes, and Financials — 8-K · Dec 1, 2025 Risk: medium
  On November 21, 2025, Solesence, Inc. entered into a Material Definitive Agreement. The company also announced the departure of directors or certain officers, t
• Solesence, Inc. Files 8-K with Financial Updates — 8-K · Nov 13, 2025 Risk: low
  On November 11, 2025, Solesence, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits,
• SOLESENCE Swings to Q3 Loss Amid Revenue Dip, Soaring Expenses — 10-Q · Nov 12, 2025 Risk: high
  SOLESENCE, INC. (SLSN) reported a significant net loss of $1.12 million for the three months ended September 30, 2025, a sharp decline from a net income of $3.0
• Solesence, Inc. Files 8-K for Material Agreement — 8-K · Nov 6, 2025 Risk: medium
  On November 6, 2025, Solesence, Inc. reported on entering into a material definitive agreement and filed financial statements and exhibits. The earliest event r
• Solesence, Inc. Announces Executive Changes and Agreements — 8-K · Sep 4, 2025 Risk: medium
  On September 3, 2025, Solesence, Inc. (formerly Nanophase Technologies Corp) entered into a material definitive agreement. The company also reported the departu
• Solesence, Inc. Files 8-K on Shareholder Vote Matters — 8-K · Aug 29, 2025 Risk: low
  On August 28, 2025, Solesence, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing was made on August 29, 2025,
• Solsence Q2 Net Income Soars 212% on Strong Product Revenue Growth — 10-Q · Aug 14, 2025 Risk: medium
  SOLESENCE, INC. (SLSN) reported a significant increase in revenue and net income for the three and six months ended June 30, 2025. Product revenue for the three
• Solesence, Inc. Files 8-K on Financials — 8-K · Jul 31, 2025 Risk: low
  Solesence, Inc. filed an 8-K on July 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhi
• SOLESENCE Sets August 28 Annual Meeting, Urges Shareholder Vote — DEF 14A · Jul 30, 2025 Risk: low
  SOLESENCE, INC. (SLSN) filed a Definitive Proxy Statement (DEF 14A) on July 30, 2025, for its Annual Meeting of Stockholders scheduled for August 28, 2025, at 8
• Solesence, Inc. Files 8-K with Bylaw Amendments and Exhibits — 8-K · Jun 9, 2025 Risk: low
  On June 3, 2025, Solesence, Inc. filed an 8-K report detailing amendments to its articles of incorporation or bylaws, and also included financial statements and
• Solesence, Inc. Files 8-K: Material Agreement — 8-K · Jun 2, 2025 Risk: medium
  On May 27, 2025, Solesence, Inc. entered into a material definitive agreement. The filing also includes Regulation FD Disclosure and Financial Statements and Ex
• Solesence, Inc. Files Q1 2025 10-Q Report — 10-Q · May 13, 2025 Risk: medium
  Solesence, Inc. filed its 10-Q report for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quart
• Solesence, Inc. Files 8-K with Financial Updates — 8-K · May 7, 2025 Risk: low
  On May 5, 2025, Solesence, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits relate
• Solesence, Inc. Files 8-K: Reg FD, Other Events, Exhibits — 8-K · Apr 7, 2025 Risk: low
  On April 4, 2025, Solesence, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes Financial Statements and E
• Nanophase Technologies Files 2024 Annual Report — 10-K · Mar 31, 2025 Risk: medium
  Nanophase Technologies Corporation filed its 10-K for the fiscal year ending December 31, 2024. The company, headquartered in Romeoville, IL, operates in the pe
• Nanophase Technologies Files 8-K on Financials — 8-K · Mar 26, 2025 Risk: low
  On March 26, 2025, NANOPHASE TECHNOLOGIES Corp (SOLESENCE, INC.) filed an 8-K report. The filing indicates the company's principal executive offices are located
• Nanophase Technologies Files 8-K for Bylaws and Exhibits — 8-K · Mar 12, 2025 Risk: low
  On March 10, 2025, Nanophase Technologies Corp. (formerly Solesence, Inc.) filed an 8-K report. The filing primarily concerns amendments to its Articles of Inco
• Nanophase Technologies Amends Articles of Incorporation — 8-K · Jan 16, 2025 Risk: low
  On June 18, 2024, Nanophase Technologies Corporation filed an 8-K report detailing amendments to its Articles of Incorporation. These changes were approved by t
• Nanophase Technologies Corp Files 8-K on Shareholder Vote Matters — 8-K · Dec 26, 2024 Risk: low
  Nanophase Technologies Corporation filed an 8-K on December 26, 2024, reporting on matters submitted to a vote of security holders as of December 18, 2024. The
• Nanophase Technologies Files Definitive Proxy Statement — DEF 14A · Dec 23, 2024 Risk: low
  Nanophase Technologies Corporation filed a Definitive Proxy Statement (DEF 14A) on December 23, 2024, for the period ending December 18, 2024. The filing pertai
• Nanophase Technologies Q3 2024 10-Q Filing — 10-Q · Nov 12, 2024 Risk: medium
  Nanophase Technologies Corp. reported its Q3 2024 results, ending September 30, 2024. The company's financial performance for the quarter and the first nine mon
• Nanophase Technologies Files 8-K on Financials — 8-K · Oct 30, 2024 Risk: low
  Nanophase Technologies Corporation filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing includes financi
• Whitmore Amends Nanophase Technologies Stake Filing — SC 13D/A · Sep 3, 2024 Risk: medium
  Bradford T. Whitmore filed an amendment (No. 20) to Schedule 13D on September 3, 2024, for Nanophase Technologies Corporation. This filing indicates a change in
• Nanophase Technologies Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Nanophase Technologies Corp. reported its Q2 2024 results, ending June 30, 2024. The company's financial performance for the quarter and the first six months of
• Nanophase Technologies Files 8-K with Financial Updates — 8-K · Aug 6, 2024 Risk: low
  On August 6, 2024, Nanophase Technologies Corporation filed an 8-K report detailing its financial results and operations. The filing includes financial statemen
• Whitmore Amends Nanophase Technologies Filing — SC 13D/A · Jun 26, 2024 Risk: low
  Bradford T. Whitmore filed an amendment (No. 19) to Schedule 13D on June 26, 2024, for Nanophase Technologies Corporation. This filing updates information regar
• Nanophase Technologies Files Definitive Proxy Statement — DEF 14A · May 31, 2024 Risk: low
  Nanophase Technologies Corporation filed a Definitive Proxy Statement (DEF 14A) on May 31, 2024, for its annual meeting on June 18, 2024. The filing outlines th
• Nanophase Technologies Corp. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  NANOPHASE TECHNOLOGIES Corp (SLSN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Nanophase Technologies Corp. reported its financial results for
• Nanophase Technologies Files 8-K on Financials — 8-K · Apr 23, 2024 Risk: low
  On April 23, 2024, Nanophase Technologies Corporation filed an 8-K report. The filing primarily concerns the company's results of operations and financial condi
• Nanophase Sells Subsidiary for $10M — 8-K · Apr 11, 2024 Risk: medium
  On April 10, 2024, Nanophase Technologies Corporation entered into a Material Definitive Agreement with an unnamed party for the sale of its subsidiary, Nanopha
• Nanophase Technologies Corp. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  NANOPHASE TECHNOLOGIES Corp (SLSN) filed a Annual Report (10-K) with the SEC on March 28, 2024. Nanophase Technologies Corporation filed its 2023 Annual Report
• Nanophase Technologies Files 8-K on Financials — 8-K · Mar 21, 2024 Risk: low
  On March 20, 2024, Nanophase Technologies Corporation filed an 8-K report detailing its financial results and exhibits. The filing includes information on the c
• Nanophase Technologies Corp Files 8-K — 8-K · Mar 5, 2024 Risk: medium
  On March 1, 2024, Nanophase Technologies Corporation entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
• Whitmore Amends Nanophase Tech 13D Filing — SC 13D/A · Mar 5, 2024 Risk: medium
  Bradford T. Whitmore filed an amendment (No. 18) to Schedule 13D on March 1, 2024, for Nanophase Technologies Corporation. The filing pertains to common stock w
• Whitmore Amends Nanophase 13D, Updates Ownership Stake — SC 13D/A · Feb 12, 2024 Risk: low
  Bradford T. Whitmore, a significant shareholder of Nanophase Technologies Corporation, filed an Amendment No. 17 to his Schedule 13D on February 8, 2024. This f

Risk Profile

Risk Assessment: Of SLSN's 37 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Solesence, INC.'s most recent 10-Q filing (Nov 12, 2025):

• Revenue: $14.597M
• Net Income: $(1.12M)
• EPS: $(0.02)
• Debt-to-Equity: 1.10
• Cash Position: $429K
• Operating Margin: -5.35%
• Total Assets: $53.987M
• Total Debt: $24.632M

Key Executives

• Jess Jankowski
• Bradford T. Whitmore

Industry Context

Solsence operates in the beauty and life sciences markets, focusing on skin health and medical diagnostics. The company leverages materials science and nanotechnology for applications in sunscreens, cosmetics, and diagnostic ingredients. The beauty and personal care industry is highly competitive, driven by innovation and consumer trends, while the medical diagnostics sector is subject to stringent regulatory requirements and technological advancements.

Top Tags

8-k (6) · material-agreement (5) · corporate-governance (5) · financials (5) · sec-filing (5) · amendment (4) · financial-results (4) · filing (4) · financial-reporting (4) · 10-Q (4)

Key Numbers

• CIK Number: 0000883107 — Unique identifier for Solesence, Inc. in SEC filings.
• Reporting Period End Date: 2026-03-31 — Indicates the end of the financial period covered by the report.
• Total Revenue: $14.597M — Decreased 13.4% from $16.866M in Q3 2024 to $14.597M in Q3 2025.
• Net Loss: $(1.12M) — Swung from a $3.045M net income in Q3 2024 to a $1.12M net loss in Q3 2025.
• Cash: $429K — Decreased significantly from $1.409M at Dec 31, 2024, to $429K at Sep 30, 2025.
• SG&A Expense: $3.069M — Increased 58.7% from $1.934M in Q3 2024 to $3.069M in Q3 2025.
• Related Party Debt: $14.816M — Total related-party lines of credit increased from $4.0M at Dec 31, 2024, to $14.816M at Sep 30, 2025.
• Gross Profit: $3.37M — Decreased 44.8% from $6.102M in Q3 2024 to $3.37M in Q3 2025.
• Net Loss Per Share - Basic: $(0.02) — Reflects the Q3 2025 net loss, down from $0.04 net income per share in Q3 2024.
• Shares Outstanding: 70,536,845 — As of November 12, 2025, indicating a slight increase from 70,103,279 shares at Dec 31, 2024.
• SEC File Number: 001-42589 — Identifies the company's filings with the SEC
• IRS Employer Identification No.: 36-3687863 — Company's tax identification number
• Product Revenue (Q2 2025): $20.261M — Increased 56.7% from $12.923M in Q2 2024
• Net Income (Q2 2025): $2.667M — Increased 211.6% from $856K in Q2 2024
• Cash (June 30, 2025): $4.108M — Increased from $1.409M at Dec 31, 2024

Forward-Looking Statements

• {"claim":"Bradford T. Whitmore will continue to be a significant shareholder in Nanophase Technologies Corporation.","entity":"Bradford T. Whitmore","targetDate":"2025-02-08","confidence":"high"}
• {"claim":"Further amendments to this Schedule 13D are likely if Whitmore's ownership percentage changes significantly.","entity":"Nanophase Technologies Corporation","targetDate":"2025-02-08","confidence":"medium"}

Related Companies

SOLES · NANX · NPHASE · NANO · NPHAX

Frequently Asked Questions